Axsome Therapeutics (AXSM) revenue breakdown
By product, Product Sales is the largest at 99% of fiscal 2025 revenue, growing 77% a year over 2 years.
Revenue by product
Fiscal years, as Axsome Therapeutics reports them in its 10-K filings; fiscal 2025 total $638M.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| Product Sales | $202M | $382M | $634M | 99% |
| Royalty and Milestone Revenue | $2M | $4M | $5M | 1% |
| License Fee | $66M | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AXSM.
Open AXSM in InvestinglyQuestions
Where does Axsome Therapeutics make its money?
In fiscal 2025, by product: Product Sales $634M, Royalty and Milestone Revenue $5M.
From Axsome Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.